Metastasiertes kastrationsresistentes Prostatakarzinom

Autor:	Christian Schwentner, F. König, S. Zastrow, Kurt Miller, Henrik Suttmann, R. Eichenauer, M-O. Grimm, P. Albers, G. Geiges, David G. Pfister, G. Mickisch
Rok vydání:	2014
Předmět:	Oncology medicine.medical_specialty business.industry Urology Treatment options Disease Castration resistant medicine.disease Prostate cancer Stable Disease Quality of life Internal medicine Medicine Position paper Therapy monitoring business
Zdroj:	Der Urologe. 53:710-714
ISSN:	1433-0563 0340-2592
DOI:	10.1007/s00120-014-3491-7
Popis:	This position paper is intended to help to structure and to standardize therapy monitoring in patients with metastatic castration-resistant prostate cancer (mCRPC). With the treatment options available today, patients with metastatic disease can often maintain good quality of life and stable disease for several years. It is crucial that once a therapy becomes insufficiently effective that it be replaced in a timely manner by a new treatment option. From a prognostic point of view, it is important that patients receive as many as possible and in the ideal case all currently available treatment options.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7806bd84e038940c52d18d0e9c29a0a0 https://doi.org/10.1007/s00120-014-3491-7 Zobrazit plný text záznamu Full text from SpringerLink